Latest Annual Report
Filed: 2026-03-31
Key Insights
- Brainstorm Cell Therapeutics' financial results showed significant volatility in 2025, with large fluctuations in revenue, margins, and net income.
- The company relied heavily on short-term loan agreements and equity offerings to fund its operations, raising concerns about its long-term financial stability.
- Brainstorm's pipeline of cell therapy products is still in development, with no clear timeline for regulatory approval and commercialization, which introduces considerable uncertainty for investors.